These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39347364)

  • 1. Octreotide Causing Hyperkalemia: A Case Report and Review of the Literature.
    Sasidharan S; John S; Puri I; Azhar M; Mallappallil M
    Cureus; 2024 Aug; 16(8):e68246. PubMed ID: 39347364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide for the treatment of sulfonylurea poisoning.
    Glatstein M; Scolnik D; Bentur Y
    Clin Toxicol (Phila); 2012 Nov; 50(9):795-804. PubMed ID: 23046209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient.
    Adabala M; Jhaveri KD; Gitman M
    Nephrol Dial Transplant; 2010 Oct; 25(10):3439-42. PubMed ID: 20610525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide therapy for recurrent refractory hypoglycemia due to sulfonylurea in diabetes-related kidney failure.
    Gonzalez RR; Zweig S; Rao J; Block R; Greene LW
    Endocr Pract; 2007; 13(4):417-23. PubMed ID: 17669721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure.
    Vallurupalli S
    Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful treatment of severe sulfonylurea-induced hypoglycemia by the subcutaneous administration of octreotide in an elderly patient with diabetes: A case report].
    Nakaya M; Oka R; Miyamoto S
    Nihon Ronen Igakkai Zasshi; 2019; 56(3):336-342. PubMed ID: 31366755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide: an antidote for sulfonylurea-induced hypoglycemia.
    McLaughlin SA; Crandall CS; McKinney PE
    Ann Emerg Med; 2000 Aug; 36(2):133-138. PubMed ID: 10918104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide for the treatment of hypoglycemia after insulin glargine overdose.
    Groth CM; Banzon ER
    J Emerg Med; 2013 Aug; 45(2):194-8. PubMed ID: 23669130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide's role in the management of sulfonylurea-induced hypoglycemia.
    Dougherty PP; Klein-Schwartz W
    J Med Toxicol; 2010 Jun; 6(2):199-206. PubMed ID: 20352540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide for sulfonylurea-induced hypoglycemia following overdose.
    Carr R; Zed PJ
    Ann Pharmacother; 2002 Nov; 36(11):1727-32. PubMed ID: 12398568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician.
    Moussavi K; Fitter S; Gabrielson SW; Koyfman A; Long B
    J Emerg Med; 2019 Jul; 57(1):36-42. PubMed ID: 31084947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide for the treatment of intentional insulin aspart overdose in a non-diabetic patient.
    Dewaal CM; McGillis E; Mink M; Lucyk S
    CJEM; 2018 Jul; 20(4):643-647. PubMed ID: 29202888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide.
    Fleseriu M; Skugor M; Chinnappa P; Siraj ES
    Endocr Pract; 2006; 12(6):635-40. PubMed ID: 17229659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses.
    Boyle PJ; Justice K; Krentz AJ; Nagy RJ; Schade DS
    J Clin Endocrinol Metab; 1993 Mar; 76(3):752-6. PubMed ID: 8445035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose.
    Gul M; Cander B; Girisgin S; Ayan M; Kocak S; Unlu A
    Adv Ther; 2006; 23(6):878-84. PubMed ID: 17276956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon.
    Mohnike K; Blankenstein O; Pfuetzner A; Pötzsch S; Schober E; Steiner S; Hardy OT; Grimberg A; van Waarde WM
    Horm Res; 2008; 70(1):59-64. PubMed ID: 18493152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current hyperkalemia interventions co-administered with a dextrose 10% solution significantly lower hypoglycemic rates (CHICA-D10).
    Ibarra F; Fountain C; Fallert T
    Am J Emerg Med; 2024 Oct; 84():120-123. PubMed ID: 39111100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide.
    Krentz AJ; Boyle PJ; Justice KM; Wright AD; Schade DS
    Diabetes Care; 1993 Jan; 16(1):184-6. PubMed ID: 8422773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemia following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function.
    Coca A; Valencia AL; Bustamante J; Mendiluce A; Floege J
    PLoS One; 2017; 12(2):e0172961. PubMed ID: 28245289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous octreotide infusion for sulfonylurea-induced hypoglycemia in a toddler.
    Llamado R; Czaja A; Stence N; Davidson J
    J Emerg Med; 2013 Dec; 45(6):e209-13. PubMed ID: 23827165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.